In this week’s video, Dr. Brian G.M. Durie explains that maintenance therapy can prolong remissions and delay relapse.

The BOTTOM LINE: If maintenance therapy is well-tolerated, stick with it!

Have a question? Submit it to

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at

Previous Post
Options for myeloma patients who have undergone Darzalex (daratumumab) therapy and relapsed
Next Post
Toxic Exposures Unleashed

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.